what was the first glp 1 Science's 2023 Breakthrough: GLP-1R Agonists GLP-1s are no longer the

In this review, we discuss the mechanism of action of GLP-1 RAs, focusing on their proposed cardiometabolic impact and the key clinical trials that have demonstrated improvement in cardiovascular outcomes

Tirzepatide, still not approved in the EU for specific use in patients with obesity, is a dual agonist of the GLP-1 receptors and another incretin, gastric inhibitor polypeptide (GIP)

10.1016/j.bbrc.2013.02.042 166

The report, published by a team from the David Geffen School of Medicine at UCLA, details cases where these incretin-based therapies triggered sensory disturbances known as dysesthesia and allodynia

If we want to know how to best use GLPs it is important to think about how we, as a society and as individuals, ended up in an obesity epidemic

A separate phase 3 trial of the long-acting agent NLY01 also missed its primary endpoint (McGarry et al., 2024)